!"#$%&'()

!"#$*+)

!,-./)

0#123284546723447

!89:;K<=>?5@ABCDE>?$FG)

No. 4672H#12I

1 137H24I

2 117H84I

3 77H74I

4 47H24I

5 27H24I

6 47H44I

7 37H34I

!JKLM$FG)

No.

1

2 N14CNo. 3OPQRA

3 N14CNo. 2OPQRA

4

No. 4672H#12I

1 17H14I

2 17H14I

3 37H34I

4 17H14I

5 17H14I

STLM

UV

47H44I

47H44I

WXY;Z[\]O89:;K1O$^_`abcRA#1deO5>fghij$kl

mnopY;qar$stbuRA5>f$vwHxb89:;KIbyBz$,{

89:;K$|}~byBz

���UINRbuRA�a�89:;K$D}�/H�a$=��I

��

��$dw'(

mnopY;O89:;K$^_`aHPubMed%&I

!=��j89:;K@ABC89:;K<=>?O$^_`aj)

#1%&3Pubmed

%e�3vitamin KOwarfarin

%&��31988/1/1��H1��%&32008/2/652��%&32009/11/5b��I

�73����UV5human5Clinical trial5Meta-analysis5Randomized controlled trial5Case

reports

%&V�#1��589:;K����< >?¡DE>?OmnopY;O$^_`a�< ��$#1�¢

£%&¤¥OV�¦£b5§¢£%&¤¥$¨©#1buVzª«¬U�7H89:;K����< >?¡DE>?OmnopY;O$^_`a�< I­���®¯V5°±RA"#�²£%&¤¥OV�¦

mnopY;O89:;K$^_`abcRA#1H¢£³´²£%&¤¥I�5§µ�b¶B*+V�¦LM·¸¹;5stº4H»¼5�¯5½F5¾¿t25ÀÁs5�aÂ$=ÃI5ÂÄÅÆÇÈgj9OVzinternational normalized ratioHINRIÉ5�aV�>?H89:;KIOÂÊHmnopY;I$FG5ËÌ�OËÌÍÎ5ÏÐ��5Ñ;ÒÓ¹;ÔÕ�´Ö`a$×Ø(5xUÙÚÔÛÜ�ÍÝ5Þt$ßg;Ô5."5àjmjÒ5�ab�A=��5Abstractor$ßg;Ô¦

áâ$>f$ãäHSTLM��I

åæLM

>?ç

JKLM$FG

��

89:;K<=Xnè89:;é

!¨©¤¥Hêt$�ab�A=��$^_`a�ë$��­5cì$=��íU#1I)

Nîï46Cï2ðb

17O2ñ�¦

4672H#12I

òóHôí�õö5÷øùßYj5àúûü5ý9þ5Û÷5ÛÈÿ!5½¨5ÛYoÈmj5"Yj;#jþ5Wý$;I

%&DEéHOsmolite, Ensure, Ensure® Plus, Isocal, Nutrilite 330I

WøýÈ

�$'$>?3Ù(W()Y5*+5,-9.ß5)h/ijþ

·j9012LM

367H214Iîï4653jþÿYj4

!"#$%&'()

!"#$*+)

!,-./)

0#123104546723 167

!89:;K<=>?5@ABCDE>?$FG)

No. 4672H#12I

1 87(44I

2 27H14I

3 27H24I

417H14IJKLMNOPQ

5 RS

6 37H34I

!TUVW$FG)

No.

1

2

3

4

No. 4672H#12I

1 17H14I

2 17H14I

3 17H14I

4 17H14I

XYVW

Z[VW

RS

27H14I

\]^_`;a89:;K$bcdeHfgh%&I

!=ijk89:;K@ABC89:;K<=>?a$bcdek)

#1%&3flgmnh

%op3vitamin Kawarfarin

%&qr31983stuH2009/5/26v%&wxI

y73z{5|}~���

%&S�#1��589:;K����<�>?�DE>?a\]^_`;a$bcde�<���$#1��

�%&��aS���v5���%&��$��#1vNS����Ry7H89:;K����<�>?�DE>?a\]^_`;a$bcde�<�I������S5���A"#���%&��aS��

\]^_`;a89:;K$bcdev��A#1H�� ¡��%&��I�5�¢£v¤B*+S��VW¥¦§;5¨©ª4Hs«5j�5MF5¬Q©25­®¨5¯e°$=±I5°²l³´µ¶k9aS�international normalized ratioHINRI·5¯eS�>?H89:;KIa°¸H\]^_`;I$FG5¹º»a¹º¼½5¾¿qr5À;Á§;{Ã�¡Äde$ÅÆ(5ÇRÈÉ{ÊË�¼Ì5Í©$ζ;{5."5Ïk\kÁ5¯ev�A=ij5Abstractor$ζ;{�

\]^_`;Ê`ÉË$°ÐvÑÒ�ºÓA89:;K¾¿»

JÔÕ46CÕ2Öv

17a2��

4672H#12I

¥k9×ØÙVW

147H94IÔÕ465ÚkÛÜ`kÝ

RS

\k^_`;Þe¨©vÃßA89:;K<=àá$¹ºâã

äåà?g$89:;K$æ-

��

§;9kçè{éêë��BAKì>?a\]^_`;a$bcde$íîjv��Aïo

!����Hð©$¯ev�A=ij$bcdetñ$���5�ò$=��óR#1I)

>?ô

TUVW$FG

õö

89:;K<=÷]ø89:;á

ùúHûüèÎ`k5ú$ýI

þÿDEáHVK¼!þÿá5^]Ê`è"®5÷]9:;®5#§;µ§;®I

"ü$µ

�$%$>?3Kì>?H&&ü;aÈ]Êü;I5ùú'(kÛ5)*+,

!"#$%&

'()*+38,-,./*+60/

!0123K4567-89:;<=67>?@&

No. ,./*A()*B

1 15/A11,B

2

14/A3,B

CDE-1/;FGHIJKL

3 13/A9,B

4 4/A4,B

5 4/A2,B

6 7/A7,B

7 3/A3,B

!MNOP>?@&

No.

1

2 C1,;No. 3QRST9

3 C1,;No. 2QRST9

4

No. ,./*A()*B

1 1/A1,B

2 1/A1,B

3 3/A3,B

4 1/A1,B

5 1/A1,B

6 1/A1,B

7 1/A1,B

8 1/A1,B

9 1/A1,B

UVWXY3Z[\>]^_IT9-6`>abAc_0123KB_d:e>"f

!ghijAk^>l[_m95no>pqr[st>uvw-xy>5z{D|()B&

6/A5,B

4/A4,B

}~�7\>0123K>�#

UVWXY3�Y��>��_�����90123K���

C��,.;�*�_

1/Q*���

,./*A()*B

��1���OP

50/A30,B��,.-����Y��

��Y3�� ¡Q0123K1Q>pqr[_xT9()¢£Q-6`¤¥¦�>§¨

�©ª«

{>¬>67+­®�®¯Y-°±-²³1´µ-¯¥¶¦��-F·67A®®©3Q­V�©3B-¸¹¶¦��-º»¼½

UVWXY3Q0123K>pqr[A'¡>¾¿$%B

!5no�0123K89:;0123K4567Q>pqr[�&

À31�ÁÂÃÄÅÆÇe:9F·67QUVWXY3Q>pqr[>ÈÉo_xT9¢£

U�WXY3Z[]^_ÊË90123K45�Ì>Í�ÎÏ

ÐG>6`>��AÑÒOPmz-Ót>,.>³B

ÔÕOP

ÑÒOP

|Ö

0123K>×ØÙ_d:e

ÚÛÜ|INR_IT9Ý[�0123K><Ø�%Al[>5�oB

uv

Þß>¢bàá

67â

MNOP>?@

Þß

0123K45�Vã0123ÌAÓt>,.>³B

¸¹AäDÇåæ-ç©ÂµY�-èéêë-ª1�-�ç-�«�ì-Hg-�YW«U�-íY�3î��-�ªï3-¹>ðB

ñò<=ÌAOsmolite, Ensure, Ensure® Plus, Isocal, Nutrilite 330-VKóôñò

Ì-WV�YÂ�®-�V123®-ëÀ3«À3®B

1.

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!1267*

!"#$%&'()*+,-./012345K#$6789:;<=>?@AB5:CDEFG:HI-

JKLMNOPQRNSTUVNWXYNZX[\

]^_`ab?=33c10d Page2559-2564(1997.10)

>?@AB5-./e67fghi1:jklmNHnopq:!"lrstuNvw-+,xyz{/|}~r/���-N%&'()*uN��)*lr/�n��T��+,x��{/�nx��{/nN+,x�o/|}~r/�

>?@AB5n2345K:���G

U�:3��?B�������2345Kr/�m2345K��)*n:���G�

1.2(4.11)

!"

1) �����10��N>?@AB5 Gjk�

2) !"+,-./�&5¡¢��£�TT£�9:;<:¤¥�1¦ND§¦�

3) 0¨12345K'©?:ª«�10¦N¬­®D§k�

¦Z¯°±²³-e67fgx´µt�/jk~!":+,-.¶�&5¡¢��£�TT£�~·¸¹H��:��nNº:���G-»�t¤¥x¼oH�

!1267*

1.3(2.5)

½]1¾¿

!"N%&'(

Kudo T.

Warfarin antagonism of natto and increase in serum vitamin K by intake of natto.

Artery. 1990;17(4):189-201

2360879

!":+)-.¶0¨12345K'©?:À¼{/�n��Ne67Áf1:jkmÂq:!":+)xyz{/�nxÃÄ{/�

�§¦xÅÆn¹Hpq:!"Ç.$%&'(:ÈÉ+,ÊË�%&�ÌaÍagN13¦�

2345KxÂq-�Î)*mN>?@AB5-ŹÏeÐ-�G¹Nº:ÑÒÐ)*lr/!"m67®-ÓÔx#Õ{�n~Ö�×t�/�¹�¹N+,q-»�tØ:ÙÚ:yzx{/ÛÜ�n�ÝÞßmEàNá§: ^FG·:âãnEst�/�äåNæçèé-ǵ/>?@AB5 Gjk-Å{/ ^êëlmNì!"míÅ-)ÛE�lJ��înêë{/ku�×ïNì!"m)ÛðñE�lJ��î

nêë{/kuǶNº:òóm«ôst�E��º�lNõÉmN�§¦-pq:!"x+,�öN2345K01÷ÚEØ:ÓÔxøÛ/

�n-.¶N�ùÐ-lmr/~N>?@AB5 Gjk:!"+,:âã-»�t�úx¼o/�n-¹H�ôHN2345KxÂà�Înûü×t�/%&'()*:+,-»�tu¤¥¹H�

!"�PubMed�2�N]1¾�1��

1.1(4.10)

!"

1) �����3��N>?@AB5 Gjk�

2) !"+,ÊË-1�1¦ND§¦�

3) !"+,ÊË-2�7¦ND§¦�

¦Z¯°±²³-e67fgx´µt�/jk~!":+,-.¶�&5¡¢��£�TT£�~·¸¹H��:��nNº:���G-»�t¤¥x¼oH�

!1267*

ZX[\Nýþÿ!N"QR\N#$%&N'()N*+D,N-./0

e67fg1:!"-./>a@AB5Ïe�G

]1:r234104 : 36-38, 1978

Pubmed 56E¹

!":+,qN+,��N��-7¦8Eؤ¥x}{/âãm9�×t�/~Ne67fg1:jk-nstN!"m:ü¹�B�%@A%3alr¶N);êë-å{/<=~|}lr/n>ü×/�

?@Aý:U�No.mNæçÊËB-ônIHÒ:No.-�C{/�DE:FG~2: HIJKN3: LúJKN4: ����NMa�NBaO��

2.

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

2.6(4.7)

!"#$%&'()*&

2.7(4.12)

!1267*

Walker FB 4th.

Myocardial infarction after diet-induced warfarin resistance.

Ann Intern Med. 1984 Oct;144(10):2089-90.

6486994

+,-./0123K/456789:;<=>%3?@AB'C"D"303EFGHIJK:LMNOP'QRS8TUOVWXGYZ[

\K]^_`,aB';<=>%3bcd/efa8gh'+,-./0123K67/ij/%kl8mnopqh'r0123K+8st

K:”u@vwxyzunderanticoagulation{”8O|On9}8K~ZN�:]

X���zCase reports'2X�{

+��/�ZOj�89�'��8��:VWXG�}@vwxy/j�G���2�/fa/X�N�:]

2.4(4.5)

!"#$%&

2.5(4.6)

!1267*

Qureshi GD, Reinders TP, Swint JJ, Slate MB.

Acquired warfarin resistance and weight-reducing diet.

Arch Intern Med. 1981 Mar;141(4):507-9.

7212893

���SN��d�/+,G67hon:fa8�noB'+,-./0123K67�/��8stK:�gSO;<=>%3?@AGYZ[\K��A��:]

X���zCase reports'2X�{

�� 'fa/¡¢/+�£z!"#$%&/¤�67{G¥¦h�\§89�';<=>%3¨A�YZ[\©ª�X�/��N�:]

¡¢/+,«0123K/¬­O11®/+¯z!"#$%'°%=±;&'²³')*&'´µ¶·'¸%&3¹&k')1k'º»)3¼»'l)¼3'½´µ¶·'¾/¿��À

The effect of dietary vitamin K on warfarin-induced anticoagulation.

J Intern Med. 1991 Jun;229(6):517-20

0123K/¬­O��zÁ}ªÂÃ'!"#$%&'Ä´µ¶·')1k{

012K/Åhn��zDÆD'´Ç»%'ȵÉÊË'1ÆÌÍ{

0123KÎÏz=ÐDÑÈÒ3{

2045759

1ÓNÔ+,-./0123K67���9Õ1000 µg��K:§'Ö×vw£A/ØÙhPOn��GÚÓFYZ[\K]Ù�'Ûsho

67K:\§89�\/ÜcBÝ�h'¡¢/+,G¥¦hoÔÚÓFBÞß�sP\§�àᩪ�]+,-./0123K67/Óâ/

j�B250-500 µgGãäOn9}8K~ZN�:]

1)  åæZçèéêëSC"D$<zObservational protocol{

2) ìæZçèéíÜîl"kÒ&*&C"D$<zRandomized crossover protocol{

;<=>%389:@vwxy/ïðA8gK:'0123K�¬­�:nBÅhn��/67/ñòGóôh�]

+,-./0123K67§@vwõ_/öïðA8mno/�÷AGø|ù8K:�SN' åæZ�9úìæZçèGûüh�]

0123K67�/jJB'ýþ@vwõ_ÿGbchon:fa/INRGj�©!:"#O$%N�:]

2.3(3.2)

!1267*

Karlson B, Leijd B, Hellström K

On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.

Acta Med Scand. 1986;220(4):347-50.

3541503

@vwõ_d'0123K�¬­O+¯z250 µg&'{/67B'$'N�ª()*OnùÔhªOn�'Ûsho67K:§+ñòG,-K��A��:]

íÜîçèzRandomized study{

!1267*

Pedersen FM, Hamberg O, Hess K, Ovesen L.2.2(2.2)

15121490

��zPubMedé8�'^d.é1�{

z/0çè{

;<=>%3õ_8�no'0123KG¬­812+3¯z!"#$%&'Á}ªÂÃ{4;Ê3/67/ñòGóôh�]

!"#$%&'Á}ªÂÃ';Ê3'0123KÎÏzKonakion®{

2.1(2.1)

+,-./0123K67§@vwõ_/öïðA8mno/�÷AGø|ù8K:�SN' åæZ�9úìæZçèGûüh�]

!1267*

Franco V, Polanczyk CA, Clausell N, Rohde LE.

Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and

randomized protocols.

Am J Med. 2004 May 15;116(10):651-6

0123K�¬­O+¯'0123K�56h�+¯

2.3(2.3)

1)  åæZçèéêëSC"D$<zObservational protocol{

2) ìæZçèéíÜîl"kÒ&*&C"D$<zRandomized crossover protocol{

!1267*

Franco V, Polanczyk CA, Clausell N, Rohde LE.

Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and

randomized protocols.

Am J Med. 2004 May 15;116(10):651-6

!1267*

Kempin SJ.

Warfarin resistance caused by broccoli.

N Engl J Med. 1983 May 19;308(20):1229-30

6843604

15121490

0123K67�/jJB'ýþ@vwõ_ÿGbchon:fa/INRGj�©!:"#O$%N�:]

z;<=>%3?@A/7%8mno/óô{

;<=>%3?@AGtXh�fa8gh'Õ/7%Gø|ù8K:�8';<=>%3/ÿ9�yG:~';<=>%3?@A8gK:r0

123K+/67/ñò8mnoóôh�]

���SN��d�/+,

!1267*

Chow WH, Chow TC, Tse TM, Tai YT, Lee WT.

Anticoagulation instability with life-threatening complication after dietary modification.

Postgrad Med J. 1990 Oct;66(780):855-7

2099431

;<=>%3¨A�;8|ª:faB'<8=>/+,?z!"#$%&@/���GAB867honOnù{8CDK~ZN�:]

X���zCase reports'1X�{

���SN¿��d�/+,EFG/jJ�;<=>%3õ_/?@AGYZ[\h'TUOQRSHIz�JKL{GMn�X���N�:]

¿��/N±Oz)1k'°!'°±PÑ'!"#$%&{

QR8��:ýþ@vwÿbcfa�+,EFGj�K:SV'0123K67�GT"8óôh'Õ/IU§ho��:jJGCDTP

VWK:X#��:]Ù�'@vwxy�ïðK:ÙNINRGAY8ËZ1&K~ZN�:]©|8'��8��:9}OVWXG[\K:

�8'+,EF/�]Oj�z<80123KG¬­8129}O+¯{B^M:9}8K:]

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

2.9(4.22)!"#$%

&'1) ()*+,-.&'2) /01

&'2342&'5

6789,:;<=>?.@AB:KCDEFGH/0DIJKCLMNOOPQ.6789,:R<?STNO&'23UVWX

!1267*

YZ[\UP NST&']^ _`-Z[abcR<d_`-Z[abcR<?efghiO4'

jDkl

mnZ[dopZ[\UP NST&'] Page141-144(2008.08)

6789,:q;=>0rstuvwxh0y.@AB:Kz{JK0|}gg~Q.JKI0��h��C��W�gUVWX

2.8(4.17)

!1267*

Beanland DR, Dorsey DA.

Monitoring warfarin therapy.

Am Fam Physician. 1999 Sep 1;60(3):764, 766

10498107

��0��y.@AB:K0���ghW��0zIJK0��h#�Q�Wg���WX

&'234Case reports.1&'5-letter��-

6789,:;<#0=>Q���.@AB:KCFG��0�hJK#�Q��.��?�P��O&'023UVWX

��

3.

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

3.8(4.23)!"#$%

&'()K*+,-./01

234562237

&'()K*+,-./016VK-./01789:;<=>?@9ABCDE=FGHIJKL'M)NOPQA-./01RST9UV

R8WDXYZ[\]^_`abcd)eYfgNhQ^-./01IijNk@\UVlNmn@A458op]_qrR9&'()KJK

stPT-INR6prothrombin time-international noralized ratio7uvwxyzN{]\mn@A_

!1267*

&'()K*+,-./01I`abcd)|}Nvwxyz

~���9����9����

/0-����|�25�6� Page481-484(2008.12)

�sI`abcd)Iij8��I���=��Z�^_�A9VKNW^����� ¡8¢£¤¥¦x^A§9`abcd)=�sZ�

^VKI¨©JKN8ª«@9`abcd)ij£IVK-./01I¬Y8­®¯°�@\8±Q9`abcd)ij£N8PT-INRhW

²VKJKs=ª«³D´µx^r�t¶·�¸¹º[A_

3.6(4.9)

Ensure Liquid

3.7(4.15)

!1267*

Oren B, Shvartzman P.

Unsuspected source of vitamin K in patients treated with anticoagulants: a case report.

Fam Pract. 1989 Jun;6(2):151-2

2663579

G23WT9`abcd)�»¼½Y=¾r@¿^ÀÁIJKNk@9ÂIW¿pÃ5=ÄYxÅÆRS^Ç

1. ���À�|=ÈÉx^ÊN9ËÌÍ=ÎÏx^_

2. ����|#Ifg89ËÌÐÑIÒÓ=45x^W¿ÔÕx^_

3. Ö×Ø×)&)£¤IÙÚ�NÛÜtS^fg89ËÌÐÑIÒÓN{]\ÎÏx^_

4. ÝÞßg89/0àáËâ#I&'()K+s=45x^_

23456Case reports91237_ã&'()K�`abcd)I»¼½YNh]\9”, �IÐÑIäå”�æçx^_

&'()K=+è/0àá1IéÚêpJKNWT9INRtÒë@A23RS^623-37_

3.4(4.4)

Isocal

3.5(4.8)

!1267*

Lee M, Schwartz RN, Sharifi R.

Warfarin resistance and vitamin K.

Ann Intern Med. 1981 Jan;94(1):140-1.

7447217

`abcd)ì)Ø×Matíîpï?Nðñ@Aº9&'()K+,Ëâ=JK@\]p]òó¿ò9ôõxÅÆRS^_

23456Case reports91237

&'()K=�D+è-./01NWT9-ö���ÀN÷@ø��=ùƾr@A23RS^_

3.2(4.2)

Ensure Plus

3.3(4.3)

!1267*

O'Reilly RA, Rytand DA.

"Resistance" to warfarin due to unrecognized vitamin K supplementation.

N Engl J Med. 1980 Jul 17;303(3):160-1.

7383081

�DIúû/0Ý18”ü[A”&'()KàýIþýÿRST9-ö���ÀN÷@®¨�I!"lø��=ùƾrx_

23456Case reports91237

�sI&'()K=+,x^/0àáËâEnsure PlusIJKNWT9`abcd)#�t$%A23RS^_

Osmolite

3.1(4.1)

/0àá16PubMedÇ749"#$Ç447

23456Case reports91237-letterWT-

!1267*

Lader E, Yang L, Clarke A.

Warfarin dosage and vitamin K in Osmolite.

Ann Intern Med. 1980 Aug;93(2):373-4.

7406391

"|&Ìg89/0àá1'&'()K1IþýÿRST9`abcd)NW^����|=()x^*+�tS^r�=õ,xÅÆRS^_

23456Case reports91237-letterWT-

-./0RJK=ÈÉ@A/0Ý1òºI&'()KàýNWT9���ÀIø��=12@A23RS^_

Ensure

23I/0àá1OsmoliteN+�[^&'()KNWT9`abcd)4�½Yt$%A23RS^_

/05Î8tBfgNh]\@6@6ÛÜ�pT9/0àá187ûlp89Nh]\æ·p:;=<¿_@ò@9r[ºIfg8=>�?2@�?A?2I12Bt*]A§9`abcd)IW¿p���ÀeYfg=�|x^"C89DEp/0àá1I/0FG6H17�¾rTI^J½Y=õ,xÅÆRS^_

23456Case reports91237-letterWT-

úû/0Ý1#Iõ,Z[\]p]&'()KàýNWT9`abcd)ø��t$%A23RS^_

Ensure

!1267*

Michaelson R, Kempin SJ, Navia B, Gold JW.

Inhibition of the hypoprothrombinemic effect of warfarin (Coumadin) by Ensure Plus, a dietary supplement.

Clin Bull. 1980;10(4):171-2.

7214706

-ö���ÀeYfgt-./01JK=ÈÉS^]8#0x^�Æ89Ö×Ø×)&)K=LMNNÚx^r�t¶·RS^_ON9fgt-./01òºPQËNR^£89dSTtUVx^*+�tST9WºX¤N¨©p���YZNp^ò'@[p]_

23456Case reports91237

[s\lR/0àáËâ=XY@A]^_`ØËÌ|}IÈÉNWT9Ö×Ø×)&)£¤IÒÓt$%A23RS^_

Nutrilite 330

!1267*

Watson AJ, Pegg M, Green JR.

Enteral feeds may antagonise warfarin.

Br Med J (Clin Res Ed). 1984 Feb 18;288(6416):557.

6421377

!1267*

Brigden ML.

When bleeding complicates oral anticoagulant therapy. How to anticipate, investigate, and treat.

Postgrad Med. 1995 Sep;98(3):153-4, 159-62, 164-5

7675740

&'()KIJKs=,«NÒÓZ�^ËÌIÒaN89bcIª«=d¿ÅÆRS^_ONINRt�|eÐNSf\'UVlNæ�pg

ÒNðñx^*+�tS^IR9�h@i.��I,j8QN��xÅÆRS^_�A9��tpDINRIklpmnI�Æ8opT9q

1p��tS^fgN÷@\8&'()KIij@rIÀÁstt¶·Np^ò'@[p]_

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*!"#$%&'()*+,-./012)'345678'9:/;<)=>?@ABC'DE'FGH4+,I/J&KLM"2)5NO

PQRS)TUVW(X4!"#$%&Y%Z[\;]6^_6`abcCNHd34e&fgh®i%jklOmnR3opqNr<stuT

3.10(4.25)vw]xy

!1267*

UVW6!"#$%&J&KLM"'z{9:/;<u|}34~YL%M��'���tu�"��&®'���tdp)���K��&6\

;N�6]�RSX4�s'4�&�&�h"��&/�����h"��Z[{�sq69:/;<uNr<st)TUVW6^_3��VOSX�B��O��ou�4BC ¡��¢£O01�tdpoq¤uT!"#$%&6(¥o¦'§¨2©ªB>O«¬�tu^_'­H4®�B?§¯C/��uB° ¡3PQRSX4�B����o^_'{±²t)©ªRS)T

³�&´�&®

3.11(4.26)vw]xy

VWµ¶·2VW¸

*+,-.]6P¹º»¼½½¾V^_'¿À)ÁÂbc ¡NHd³�&´�&®'()ÃÄqs6` bc./01HuN5Å4!M

#$%&®/ÆÇHd{+,IÈÉ/ÊË2)5NOÌÍÎ4º»¼ÏÐ6ÑÒÓOÑÔ�t)ÕÖ'o¤u2VW'×pd6µ¶RS)T

!1267*!"#$%&Y%Z[78O³�&´�&

®RØÙ�tu2W

ÚÛÜÝ4Þßà�Ý4áâãä4åæçè

bc-éêNë-ì17í2î Page291-295(2000.05)

3.9(4.24)vw]xy

]ïðñbcò�ó��&C·#"Y%kô®¸

VWµ¶·3VW¸

õö÷ø6!"#$%&�A^_6¥ù4ò�ó��&C��~YL%M��RS)#"Y%kô®/@AHu3VW'¿pd4#"Y%kô

®

\;ú½6!"#$%&AÇNû�+,I6üý/þÿHuT

#"Y%kô®N!"#$%&O@A�tu¡!34~YL%M��«¬"6w#6�$%&N4'"4BC(R#"Y%kô

®þC"'®�

\B°/)�Hdpoq¤u5NO|}Nr<st)T

!1267*

!"#$%&Y%Z[N]ïðñbcò�ó��&C6*+,A

-.�4á/0142345467849:;4</=>4?/;@

AU÷øBC#BCxì43í7î Page907-911(2007.07)

!"#$%&�A^_Oò�ó��&C��~YL%M��RS)#"Y%kô®/@A2)N4?D!"#$%&\;Ç3E2F�¨'ÆG

H4KL&H�IKJ6üKL316%M¤uTN¤d4!"#$%&�A^_']ïðñbc/1±Hò�ó��&C/\;2)O�4ó��

&KP��ò�ó��&C6QROSQRS)THqH4ó��&KP��ò�ó��&C6TUVA34ó��&KWXVNo)YIÓOS

)TZ[\C6ó��&K�Ç3100 µg/A]õN^_�tdp)6R4Z[\C6@A'(X4û�+,I`69:/zab'HoOs

ó��&K6cdOYINr<st)T

eaVfg^_'­H!"#$%&O\;�tuO4~YL%M��'���tu�"��&®'���tdpu���K��&6\;N�6

]�'(X4INR6J&KLM"O%ã'o¤uVWRS)Thu4UVW6^_'3��VOSX4�B��O��ou�4BC ¡��¢£O01�tdpoq¤uT

�B����^_`6Bij«¬kl6SQÓìeaVfg^_'¿À)!"#$%&J&KLM"6VWmn

o:pq4r/ps

AU÷øBC#BCxì41í7î Page863-866(2005.07)

~YL%M��'���tuò�ó��&C·�"��&®¸

VWµ¶·1VW¸

4.

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

5.

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

5.4(4.27)!"#$%

&'()*+,-./

012341015

6789:;<&'()*+,-./<=>?@ABCDEFGHIJ@KLMN01=23OPQR

!1267*

STUV=DEFGWXY?Z=[\

]^_`abcdefgbhijkblmnobpqrsbtuvwbxyzb{|}~��

�q�������$b40: p949-950b2004

6789:;�?���&'()*+,-./�>?�Q<b�FGY?=���Q�H��PQ=Ob�=�����Q��OPQR�NbSTUV=�?���� ¡U¢� @[\�£�Q�H��b¤¥Y?¦§O�¨©bSTUV=ª«¬�?@AQh­=®¯°£¡±²��³´�µ¶QN·b����?�Q¸@¹º¨»2¼½�MC¾©¿<�ÀÁ=��IJÂÃÄÅ@ƾCÇÈ<ÉʶQR

5.3(2.5)

!"#$%

ËÌb&'()

SÍÎ�ÏÐ<MNÑÒ=ËÌÆAÓ&'()=ÔÕ��Ö×4&'ØÙÚÛÚ b13Î5

SÍÎ@ÑÒ=ËÌ���ÜÝbÞßà;KD#áâ¨ã=äå�æ�Q¿<@Açbèéê@O�PQ�b6789:;�?��=ËÌ�

�=ëì@í¾C´î�ï�NR�NbÞßà;K�ª©*ð<ñʶC¾Q&'()UV=��@í¾C³òóMNR

!1267*

5.1(4.13)

ËÌôÓ&'()UV��@AQD#Þßà;KôÓFGõZ=[\ö6789:;=¹n¨�?=N·@

÷{øùbúy`ûbüýþÿb!"#b$"%&

"�'(Ú)7ö33*10+ Page2559-2564(1997.10)

5.2(4.14) !1267*

Ohkawa S, Yoneda Y, Ohsumi Y, Tabuchi M.

[Warfarin therapy and chlorella]

Rinsho Shinkeigaku. 1995 Jul;35(7):806-7

8777808

&'()���Ò<��,èb-Î.�´L���OPQ�b6789:;=/0���ÜÝQ1aOPQ�H��*ðRÀÁb6789:

;2�#=��OTT3@äå�4µ¶Q<��b&'()=��³56�QÇÈ�PQR

4.2(4.19)

&'()

!1267*

Kurnik D, Lubetsky A, Loebstein R, Almog S, Halkin H.

Multivitamin supplements may affect warfarin anticoagulation in susceptible patients.

Ann Pharmacother. 2003 Nov;37(11):1603-6

14565795

7�µ=&:89&@:��Q��=12%�;Þßà;K1(<7¦BN=Ob¿=A=¨;Þßà;K1>?=���ÑÒ=Þßà;K1��@

AQä@@ÏMC³INR�±A@BC�Q<DEMC¾QR�FG2�#=���bÞßà;K*+F7GÞßà;�=�?�23MbHI

"��FG2��J§C¾Q��@ƾCbK@INR=L,M¨¾ä@@MNMN<�b�=A=¨OP:Q;R=�?@í¾CS,ê@æT�Q��OPQR

25 µg=Þßà;K1*+F7GÞßà;���Íê@��UVPQ¾�#WMNX0binternational normalized ratio 4INR5�2�Y

Z[PQ¾�Z÷@¨BN3Î=��4=\2Î�®]¨^>0�>_5@í¾C=23OPQRÞßà;K1`a0=+�b4Dc#Þßà;

K1(<75=æT³dBNR

Þßà;K*+F7GÞßà;�

&'()4PubMede22b"#$e225

01234Case reports!1"#5-letterAç-

&'()��UV@Açb6Ú89:;=�FGY?���MN01OPQR

Þßà;K*+F7GÞßà;�

4.1(2.4)

!1267*

Kurnik D, Loebstein R, Rabinovitz H, Austerweil N, Halkin H, Almog S.

Over-the-counter vitamin K1-containing multivitamin supplements disrupt warfarin anticoagulation in vitamin K1-

depleted patients. A prospective, controlled trial.

Thromb Haemost. 2004 Nov;92(5):1018-24

15543329

Dc#;Þßà;K1(<7=�FG2�#���bfg=Þßà;K1*+F7GÞßà;���@AçINR�;÷MNR¿¶Açb¿=��

�ÑÒ=Þßà;K1��OPBC³Ah@BCMb�FG>?=iS��jk@ܵ�¿<�lmܶNR

01234Case reports!3"#5bÞßà;K`a�=æT

!1267*

noop

&'()�6Ú89:;=�FGY?����Q

�q�$b82(2): 137 1993

Pubmed rs¨M

Þßà;K*+F7GÞßà;�e4t4225

uv�wxòyzÖ×4Prospective open-label controlled trial5

;ÆAÓ:Í=Þßà;K1>?=6789:;�?��@ƾCb;?Ò=Þßà;K1�*ðfg=F7GÞßà;���=[\�òóM

NR

&'()�6789:;=�FGY?����Q=O{|�ÇÈOPQR

01234Case reports!1"#5

&'()��UV@Açb6789:;}�Y?�~�N01OPQR

&'()

6789:;@AQ�FG� �d#=��O�bN<�ÑÒ=ËÌOPBC³b��@���X��QÇÈ�PQRܵ@b&'()UV³bSTUVOPQ¿<�µý,è������Q¿<�´L�Q<b�����QÇÈ�PQR

6.

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

!"#$%&'()'*

!+,-./0*

!1234*

!PMID*

!51*

6.7(4.30)!"#$%

&'()

*+,-.1*+/

0123456789:;<=>?@AB4C5DE&'()F6G89:@012345HIJKLMNOPQRSJTUVWX6YZ9[,-\]<^

!1267*

E&'()FME012345FMJ_8`abcdJefghi6Q9[1+

#jkl@mnlo

pqrYs&gtuvgwxyy$@40: p1-6, 2006

z{|}@z~����@zN��V�����J[�0123456789:;<=>�����`]<^�[AB4C5D6i8�<����9:;<^�J�I@��9V;K��8J���<��?c��:;<^01234578#J=>?AB4C5D6���< ¡@

¢£¤5KJ¥¦6§¨�<©ª?«¬\]<^�[@��9V;efghiJ��J­@®J¯�8°±`AB4C5DJ_8?²³J´µ¶\]<�M6·¸`�¹º»\]<^

6.6(4.29)!"#$%

¼½¾¿1À

*+,-.1*+/

0Á234578=>6Â<M»`�@ÃÄ`789:;<®ÅÆÇÈÉÊ1£@ËÌÆÍÎJÏÐV��\@ÑÒJ=>6ÓbÔÕÖ×

`ØÙ6ÚÛܬ?]<^ÝÞ@ßÒJ¬³`abDà5áâÀDã.TTã/?ä}9[1=>`Øå9@0Á2345æçG8J[�`zèé:;VéêëVìV;�M�íî6Èï9[^

!1267*

Warfarin78=>JDà5áâÀD(TT)ãä}`ð�<ñò6¥�[1*+

#óôõ@ö÷ø@ùúkû@üýþÿ@ú!"#@$%&'

(ó)*+,"$-30.1/ Page47-50(1998.10)

ÝÞ�0Á234560e12@Àâà34MJ_8`5;:ñò9[?@1+`�67@Ý8�9:6;�:ÑÒJ<1À`][<�M?&

Ì\]<^�[@0Á234578=>`M�:«¬\]<¢£¤5K¥¦=�>?)@ËA`�B¹CDEê:Fì7@[MG7®©ªJ­

0Á2345M¢£¤5KJHIb6ÏÐ9:�ì�[M9:�@Jì7`KÓ9:9�Û´µ¶�&;`]<^�[@L`MîìV;[�`NO?�9:P:V;=VJ`QR9:9�Û�M�]bG<^˺1�SD`M�:i`HIbT¹UbVWV;�J\]<Xé`@YÒVËAM®1MJK��8�«¬\]<^

6.5(4.28)!"#$%

Z[ËA.AAà5@\Á]à5/

*+,-.1*+/

^_�`a*`z{|}6¡_�<Mbz{`��6cd�<ed?c¹Vb@�J��cd6���<[�`0Á2345?8;ìê

<^ÝÞ�@0Á23456fgç9¹789:;[`�îîIì7@¢£¤5K6h¹¥ÕZ[ËAJKÓ`abDà5áâÀDã?iWX9@&j}k��*6»[9[*+J,-\]<^

!1267*

Z[ËAKÓ8`warfarinJ�8?l�b&j}k��*6m*9[^_�`a*J1+

noZ>@pq¦lõ@#órõ@sotu@vúwx@µyz@{¼o|}@oW~

z~-33.6/ Page525-528(2001.06)

��¾¿1À

Coumadin resistance and the vitamin supplement "Noni".

Am J Hematol. 2004 Sep;77(1):103

15307118

6.2(4.16)

��£��

6.3(4.20)

!1267*

Taylor JR, Wilt VM.

Probable antagonism of warfarin by green tea.

Ann Pharmacother. 1999 Apr;33(4):426-8

10332534

0Á2345��i`¦H¶Jc;Y�0��®\]<?@�J®1@ËAÆ+�MJK��8J´µ¶?]<[���V��£45�

?ܬ\]<^¢£¤5K�0Á2345J�8`�0�<�M?a¹Jìê:;<J\@¢£¤5KJ]�bJìê:;V;���6Uìî`

�<�M�«¬\]<^�ê[F�\�¢£¤5K=?�¹V<?@�J<1À\�&=J��J�8`ab@INR?���`¦ÙVäf6��9[�M6��:;<^�ê�G@0Á234567®9:;<=>`35£¢¿1�<M»�@®Å ?�Ë1Jäf`5;:¡��`¢É�<�M?£ðܬ\]<^

*+,-.Case reports!1"#/

h¹Jz�¤¥3¦5D§J]<=>`F;:@0Á2345¨©#`��£��6G89[M»J¦ª�8`5;:J*+\]<^

\A«A�4

6.1(4.18)

�J�JËA.PubMed¬\A«A�4@��@��£��@��¾¿1À/@."#$¬¼½¾¿1À@AAà5M\Á]à5@&'()/

*+,-.Case reports!1"#/

0Á234578#J=>?@­®J\A«A�46¥Õ�96h=`KÓ9@international normalized ratio .INR/?äf9[=>J*+\]<^

!1267*

Bartle WR, Madorin P, Ferland G.

Seaweed, vitamin K, and warfarin.

Am J Health Syst Pharm. 2001 Dec 1;58(23):2300

!1267*

Kuykendall JR, Houle MD, Rhodes RS.

Possible warfarin failure due to interaction with smokeless tobacco.

Ann Pharmacother. 2004 Apr;38(4):595-7

14766993

11763808

\A«A�46¥Õ�9Æ�JËA�¢£¤5K¥¦¶ËAJ4ÀD`¥�<º»\]b@�êì�å¯INRJ°;6.>Ä�`/±²<î�

9êV;^9î9@¢£¤5KKÓ`a<äf?>Ä�\]êë@0Á2345³´=Jäf6ܬM9V;XµÛ^

*+,-.Case reports!1"#/

��M0Á2345JK��8`5;:J*+\]<^

��

¶Þ`I[<zN��Æ·¸#§J]<=>J0Á2345¨©J¹ªJ+\]<^�J=>JºÖ»¥¼=J½¾`ð9@��£��J¿�î5ÀÁ`G89[�MJÂÃ�ÄÅ\»V;^0Á234578#`��£��6G8�<�M�@h¹J=>`ð9ØÙ�<ܬ?]<^�JK��8�@2ÆàÇ�56¥�£��`¥�ê<®Èg�`ɶJ]<��Ê`HË9:;<´µ¶?]<^0Á2345¨

©#`��£��6G89:;<=>�@INR@�Ì#0Á2345ÍdM�Î#¢£¤5KϦÁJ��£45�6Ы`¾Ûº»\]<^

*+,-.Case reports!1"#/-letterab-

�Ñz~�6G89:;<=>`F;:@0�Ò��ÅJ78#@¢£¤5K6¥Õ”��”KÓJ[�`Ó¶?e�[*+\]<^

h¹J=>�AB4C5D6"®AMñG:Fì7@”®1K��8”6ñÔ9:;V;î�9êV;^�9@0Á2345Æ0�Ò��Å67

89:;<Vì@”��¾¿1À”���V;aÛ`Õ

Carr ME, Klotz J, Bergeron M.

Z[ËA`�@�J¶ÖWסJØÙS?Ú�Eê:;<�M?]<^=>��J*�JÛÜ6Ý�@]<;�EZ[FJÞß`�à9:

Z[ËA6�`�<�M?�áEê<^0Á2345G8#J=>`�@âãÆ¢£¤5K6h¹¥¦�<¼½`H�<ØÙ°±`@Z[Ë

A6KÓ�<­`��JdM`¢£¤5K?¥¦Eê:;V;�M6�Ï�<ܬ?]<^

6.4(4.21) !1267*

7.!"#$%&'(

!)*+,(

!PMID(

!-)(

!"#$%&'(

!)*+,(

!PMID(

!-)(

!"#$%&'(

!)*+,(

!PMID(

!-)(

7.3(3.4)

7.1(3.1)

7.2(3.3)

!)*./(

Lubetsky A, Dekel-Stern E, Chetrit A, Lubin F, Halkin H.

Vitamin K intake and sensitivity to warfarin in patients consuming regular diets.

Thromb Haemost. 1999 Mar;81(3):396-9.

10102468

Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin.

Br J Haematol. 2004 Feb;124(3):348-54.

!"#$%&'()*+,$-./0123456789/-:*;<=>?@6K%&=AB/C)(DE'FG

!"=#H=ABIJKLMNOPQ3RI3SPJKLMIObservational studyP

14717783

15886802

!)*./(

!"#$%&'()*TUVWXY=+,=32%Z0250 µg/;[\=>?@6K%&/NO123456]^_`ab'()FG

IJKLMP

#Hcd=>?@6Kefg=%&0hiY>?@6KjklNm123456/N*TUV=no_e=pq_/C)(DE'FG

!)*./(

Khan T, Wynne H, Wood P, Torrance A, Hankey C, Avery P, Kesteven P, Kamali F.

>?@6K$;<rs:*teZTUVu$vwxy*Fz={|}~�O0TUV=�vw_/-:*#H��=>?@6K%&9=��=ABZ��)e��d�*G'c'0��t=�u_/C)(Zxd�*��`78~�*G

�w9=>?@6K$rs:*teZ0TUVu=��$��'123456X}=v�_$�z*G

IJKLMP

TUVu=�vw�+,=>?@6K%&9e123456no_e=p�/C)(DE'FG

Sconce E, Khan T, Mason J, Noble F, Wynne H, Kamali F.

Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of

anticoagulation.

Thromb Haemost. 2005 May;93(5):872-5.

1.!"#$%&'(

!)*+,(

!PMID(

!-)(

2.!"#$%&'(

!)*+,(

!PMID(

!-)(

3.!"#$%&'(

!)*+,(

!PMID(

!-)(

!"#$%&'(

!)*+,(

!PMID(

!-)(

!"#$%&'(

!)*+,(

!PMID(

!-)(

4.!"#$%&'(

!)*+,(

!PMID(

!-)(

5.!"#$%&'(

!)*+,(

!PMID(

!-)(

!"#$%&'()*+,$K1)-./0123456789):;<=>?@-ABC1DE1FG

4

6789ELiterature reviewG:=>?@-AB

!"#$%&'();<HI-*+,$K1)-./01234567EJKFLGMNOPQRSTU:VWXYZ[\]-^_2;<`

'M45a\b<_cd1ef5ghi:jkl-*+,$KMmn;<MoPQR

!)*./(

Booth SL, Charnley JM, Sadowski JA, Saltzman E, Bovill EG, Cushman M.

Dietary vitamin K1 and stability of oral anticoagulation: proposal of a diet with constant vitamin K1 content.

Thromb Haemost. 1997 Mar;77(3):504-9.

9066002

6789-pq:*+,$K)rstu#$-./01-FLv:wxy;z]-*+,$Kml2g{U|}ef5)wh~�eviwHy

P�iwRPHP:;<HIjkl-*+,$K��v��-*+,$K��M�xQ�2�Ne�5�)co��QR�PU:��-RDA2

.�45ghi�kPQ*+,$K1��c��i;<=>?@MFLPQR��:;<��-*+,$K1)rstu#$)-./01M}IH

245Q�-��f����c�Ne��:��eFLPQ;<- ¡¢£¡$v�-ghi¤¥2¦wUd1��5HyP�iwR

5

§*?@E*+,$K)rstu#$23¨PQ©ª-«¬­G

rstu#$®1]-^_2¯45:;<-°±E²2*+,$KG2xwU-³|

!)*./(

Booth SL, Centurelli MA.

Vitamin K: a practical guide to the dietary management of patients on warfarin.

Nutr Rev. 1999 Sep;57(9 Pt 1):288-96.

10568341

rstu#$-XYZ012¯45*+,$K-1l013´v:µ¶·¸��Uwiw-e:��-RDAe�565-80 µg/�M¹Q4g

hijkl-*+,$KM��45�)v:rstu#$®1]-^_2¯P:ºy»�¼���i½¾)¿TI�5R

3.1

ÀÁ-8±½¾C1DE1FG

*+,$K-ÂÃÄ2xwUC1DE1FG *ÅÆÇÈÉ�5HÊE1970ÅË�vÌÍ45iÎR�µ�Ïw67v:ÐÑÒ2Ó�5��Òy�5Q�G

2

��fÔÕÖ!×ØÙ@Ú@��Eprospective open label crossover studyG

VWXYZÛeINRcÜ�ki^_2¯45*+,$KÝÃ-��f¤¥

!)*./(

Ford SK, Misita CP, Shilliday BB, Malone RM, Moore CG, Moll S.

Prospective study of supplemental vitamin K therapy in patients on oral anticoagulants with unstable international

normalized.

J Thromb Thrombolysis, 24, 23-27, 2007

*+,$KMÝÃ45�)v:�kPQXYZ�MÞ5¶�eiß:rstu#$\¾2g5�àiá01-â�MãI4)¿TI�5R

3.3

§ä×Øå!æçèéêERetrospective analysisG

XYZë$ä×@sMì�5í1l-*+,$K��

!)*./(

Reese AM, Farnett LE, Lyons RM, Patel B, Morgan L, Bussey HI.

Low-dose vitamin K to augment anticoagulation control.

Pharmacotherapy 25: 1746-1751, 2005

16305294

��:îl-*+,$KMVWï2ÝÃ45�)v:ð¤¥-^_2¦wU:[\ñò©2¼{QINRó)¼{Uw5ôõMö÷2øS�

ù:INR-úûMíü�ùQR

*+,$KMÝÃ45�)v:ýß-^_eINR-úûcãî45HyP�iwc:þi5àÿ!Hx"#2~Q5Ö$c�Ne�5Rð��-pqv:�-ghi��-%&¡$M'(@ä45y-e�)hR

Ü�kiINR2¯45í1l*+,$K-ÝÃ*qE+1-ö*ÒGC3DE3FG

3.2

,0-.�ÕÖ/£012345��Edouble-blinded, randomized, placebo-controlled parallel design studyG

rstu#$67Ò289Ü}-úûc�5^_2¯P:*+,$K-VWïÝÃvXYZ�-�kÒM:;45�)cef5

!)*./(

Sconce E, Avery P, Wynne H, Kamali F.

Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in

response to warfarin.

Blood. 2007 Mar 15;109(6):2419-23

17110451

E����G

XYZ��-�kÒ23¨PQ*+,$K-<=)>äHI-ÂÃ

!)*./(

Udall JA.

Human sources and absorption of vitamin K in relation to anticoagulation stability.

JAMA. 1965 Oct 11;194(2):127-9.

17323135

5897315

?©@A2g5*+,$KBC22D;<��-*+,$Kv:¦�Iß>ä2¦�5*+,$KÂÃ-àfiEFMGhR

rstu#$)*+,$K-./01

67-+¡äs#ØäCH¿IJ

1

E����G

rstu#$®1]-^_cKLiMN]*+,$KOPQRMS��iwQ�-TUiÀÁ-8±½¾-Ö$

!)*./(

Homma K, Wakana N, Suzuki Y, Nukui M, Daimatsu T, Tanaka E, Tanaka K, Koga Y, Nakajima Y, Nakazawa H.

Treatment of natto, a fermented soybean preparation, to prevent excessive plasma vitamin K concentrations in

patients taking warfarin.

J Nutr Sci Vitaminol (Tokyo). 2006 Oct;52(5):297-301

17190098

ÀÁMVe5�)2g{UBacillus subtiliscWXP:�-ÀÁ�;�2¦wUy23ï�kPQMN]*+,$KOPcYZef5Rb{U:rstu#$®1^_2¦wUy:ö[01iP2VeQÀÁM;D5�)cef5HyP�iwR

rstu#$®1]-^_2¯45:;<-°±E²2*+,$KG2xwU-³|C1DE1FG

6.!"#$%&'(

!)*+,(

!PMID(

!-)(

7.!"#$%&'(

!)*+,(

!PMID(

!-)(

8.!"#$%&'(

!)*+,(

!PMID(

!-)(

9.!"#$%&'(

!)*+,(

!PMID(

!-)(

!"#$

Nutrition Support Journal, 5(2), p20-22, 2004

%&'()*+,-./012345%&'()*678934-:;<=>?5@AB&C9DBE*KFGH9IJKLMNOPQR2ST-U2VW=5XYZ[A@\A]><^_`Kab<534O_`K'cAdefgR2SThU2V

%&'()*i)j]9klOmnK,o2DBE*KFGHp1qr1`s

tuvw89DBE*K9xyp1qr1`s

z^9tuvw{|DBE*K1K}~<5K2�z�}~01�{�=VW=5��tuvwKF�<=��51�M=�20-380 µg9DBE

*K-FG012>��01=V�I9����5%A'()*6749��5tuvwFG-+k��OmnK,o2���-U2�>-�|{>��=V

�� �� , 8� �� , ��  ¡¢ , £¤ ¥¦ , §¨ ©� , ª« ¬­

�w®¯°±² 47(2), 85-88, 2006

8(N8²)

³´�w><^µ¶-·¸tuvw8O�5¹º><^»A&5¼½¾¿5ÀÁÂÃÄÅ�ÆÇ¿�ÈÉÊ9˸ÌÍCU�5�1|O�

ÎODBE*K-Ï�ÐW12�>-Ñ|1^¸2V<{<5³´�w><^ÒÓ01=ÔÕ�Ö×9tuvw89DBE*KOظ^�5Ù9

ÐbÚ×��|{O��^Å|Û5vw9ÜÝOhDBE*KÐbH�Þß01^¸�¸�>-ϸVÙ�C5àá01^¸2âãäåæÅ�

Æçè9tuvwOظ^5DBE*K9xyKé¸5ÐbÚ×Kêë<5Ù9��{|Úì91�M=�FGH9��Ké�=VW=5¤íîïAðOظ^hxyKé�=V

!)*./(

tuvw89DBE*K9xy

êë

9(N8²)

êë

%&'()*ñ7OmnK,o2DBE*KFGH5klKòó�¸DBE*KÐH9ôAõAöÃ*9b÷Oظ^V

%&'()*9l�Køù0ú2DBE*KHû�9üý�þÿK!"=#5À$B)*%>&'êëKé�=V

!)*./(

%&'()*i)j]9klOmnK,o2DBE*KFGH

³´�w98O�(gÁ)ö*(+,*(tu*�È5DBE*K-Ï�ÐW12�>-Ñ|1^¸2h9�-Oh5Ï�9vw98ODBE*K-

ÐW1^¸2�>-�|{>��=VW=5Ù1|9vwO�DBE*KKÏHOÐ.h9hU�=V�1��5%&'()*6734�5/w012C��5�x34K5xOê65{Ø5N78k97O:;O<=<=IC5³´�wK>7R2�>-STCU2>?@12V

%A'()*6734OÅ22DBE*KÐbv99+,AB p1qr1`s

7(N8²)

CD

EFgG)*HIJKk9%&'()*i)j]r%A'()*®sK678934C�5DBE*KLMFGO��%A'()*

®9l�Køù

0ú2=#5NO-STCU2V<{<5%A'()*®9l�OPQRDBE*K9FGH9mnOظ^5�R�ASK4<=`T��

¸VÙ�C5UV_`K#O5%A'()*®>TPNrtotal parenteral nutirtion; 8WXYXYs7Z�DBE*9Å�ÆE[XY9>9

<\ñ7K5mn9]�¸^Ox_<=V

!)*./(

%A'()*6734OÅ22DBE*KÐbv99+,AB

`a�¢58b¬�5c¨de

NkîfAg&h39i7j Page2072-2079(2003.07)

kl5mØ9n§><^5%A'()*®6734OTPN7Z�DBE*9Å�ÆE[XY9KopR2ì�5�9x_3K>7R2�>K

Pq<5W=�r<=¸V

Ã*BAsf@át01^¸2³´�w>%&'()*>9<\ñ79þÿ�OuR2êë p1qr1`s

6(N8²)

êë

vw5x-yC�³´�w-NnKz#^Å�5{|}~8Oh5�;}~8934950%5:;89349�15%-³´�wKF

G<^¸2>9`T-U2�>{|5}~k>9<\ñ7O�2³´��Oظ^5NOR2ST-U2V%&'()*>DBE*K9<\ñ

7���Ñ|1^Å�5+,8tu�FGK�o2�>-�W<¸>01^¸2V<{<5�1|9�w�-OhDBE*KKÏHOÐ.³´�w-�w<^¸2���-U�55xOêëR2ST-U2Vk�5Ã*BAsf@C�:���³´�wONn<5%&'()*>9<\ñ79þÿ�Oظ^êë<=V

!)*./(

Ã*BAsf@át01^¸2³´�w>%&'()*>9<\ñ79þÿ�OuR2êë

�Ï��5�¨��

N°>k°h51i2j Page343-345(2004.02)

!"#$%&'()*+'K,-./01234,56,789:;"#$%&'<.=>?)*+'K@2ABCDEFGABHIJK/LMNOP1Q:RSTUV(/01WXYZ.,[\C]^_P`;a/bc56Cdefg&eh/0156?ijk50l;mn305o;pqrsCturs/0

156:10lkmn95o_PvUw

"#$%&'()*+'K,xyZ.

234k)*+'KP1Q:)*+'K@2AB(,xyZ.o

!WXYz3,{|U}~�

�����>�,56�T/;���S_����,U�/i�,��LMHNOTUw

�����,U�/DEFG�,LMHNOTUw�A{�H�/[�TUw

!V��:a/bc56/01�,_;23Z.H{|U)*+'KLM�:25-6000 µg/d,��_ ���Uw

!"#$%&',WXYZ./¡¢H£¤TU)*+'K@2AB,¥¦:;DEFG�kOsmolite;

Ensure;Ensure Plus;Isocal;Nutrilite 330;VK§¨DE�;$#©&ª«®;¬#*+'®;­®'

¯®'®�15l;mn115o;°±k14l;mn35;²³15:�´µ¶·¸¹o;��kº²�»¼;½¾ª¿&e;ÀÁ­;Ã*f;ÄÅ;©¯gÆ;/»|»;©&$¯"e;Ç&e'Èef;«ÃÉ';�,Ê�12l;mn95o;«¾Ã¯k4l;mn45o;)*+'K@2¬#Ë)*+'�k4l;mn25o;ÌÍ

«ÍÎ&k1l;mn15o;ÏÐk1l;mn15o;ÑÒ*Ó¿k1l;mn15o;ÎÔÕÖefk1l;mn

15o;��AB,Í;'(Ì#©¾'k1l;mn15o;��ÕÖefk1l;mn15o;7×ØÙk1

l;mn15o_PvUw

Ú"#$%&'()*+'K,xyZ./ÛÜ1Ým56/ÞQßà

!23Z.?{|Uá,¶âã(Tß;789?}~AB,LMRS/0`ä,WXYåæ/çèTßQUw

!"#$%&'()*+,$%-.!1"#$%&'()*K+,-./012

345$6789:;<=$>.?@A80 µg/"&'()*K+,BCDEFG=H

"IEJ+,B50 µg/"KL.J=M@6789:BN34.J=OPQBG=H

RS@"IEJ'()*K+,-B250 µg/";TU=M@VWXYZ*[\QB]^_=$>@250

µg/"?TUJ0`a._=H

!'()*K+,-b4&cdEJeUS2

-/0123456789:;<+=>2010?@A8II B&CDEFGKHIJKLMNO-

fF'()*K&ghiBjk.l>mn=&?op78&qr&sFG=Htu1@v9F?wI

Jop78P;xy_=&.z{J'()*K+,-;c|M51}w+,-;b4_=&B~#F

G�aH5�5@�.��='()*K��N�&��FG=op�]�W���W������W�*

�ucOC���?@���M?��5$��&����FG%@ucOC;]^� =$>.?@¡¢F7

8��&£Q�.z{J-¤¥���¦§500 µg/"�;{_=¨MB©�n10=H¨n`%@��

&ª«.z{J'()*Kz{-?@o¬�­�W���W�®¯°¯*'*;��M_=±².³´

1µ0OPQBeUmn=H5�5@¶}J�&·¸9:;xy_=$>.@'()*K.`=����

�W�*&¶¹º&�W���W�Bz{�»a�?¼½NjFG=H�m.@'()*K¾®Z¿*°

ÀÁ.`=��ÂÃÄ&ÅÆ.Ç_=¿(ÈÉZ��BÊË�n10=B@45 mgM0aµ-&¿É�

Ì*ÀÁ.`=Í&FG=H¤¥`%@ÎÏEJgh9:;ÐÑFÒ=+,-�1 µg/kgÓÔ/"Õ��;Ö3-M_=¨MB}#FG=MeUmn=H

×ØtÙÚ�×Û@ÜÝÛ@Þßà�&áâãäVWXYZ*å�æÚ.�01@çè�n='()*K+,Séê

!'()*K+,&ëìí./012

'()*K+,&"î&”RïEJ”ëì?@100 µgðñ._´ÒFG%@250 µg/";TUJ0`a

._=�'()*KB100 µgòó_=M@INR?0.2]^_=M&ÊËG%�H$½5@¨&9:B3-4"

ôõöM@678÷Ø.øù;úû_OPQBG=H

1000 µgÕ�&��-&'()*K+,?@üÐ+,FGu1ÍÑ�=´ÒFG=H

RS@'()*Ý.ýþ�n10=`aJ25 µgÕ�&Æ-&'()*KFGu1Í@ÿ&+,B!"G

=0?�#�n$9:B2$ôöm0õöM@678P.øù;úû_OPQBG=H$½5@"IE

.'()*K+,-Bµ0æÚ.�01?@øù&J0±²ÍG=H

ÿ51@"IE.'()*K&%&J'(&)*;+º_=½�FJö@'Ù�m&'()*K+,;R4._=¨MBÔ{FG=H

!6789:BN34JæÚ.,5---2

.I/mn10=`aJN34Q&0�BJ0&.@INRBëì_=æÚ.,51?@"IE.100-

150 µgÕ�&'()*K;12_=M@VWXYZ*&ò-;3aB@6789:B34_=OPQB

G=H¨n?@R4-&'()*K;12_=¨M.`%@"î&'()*K+,-&ëìBÅ=Ù.`=

MeUmn10=HINR&ëì&c|M51@45667¤8.INRB3Ð÷Ø9:.J=@G=0?V

WXYZ*&�-ë;BÆJöMÍ3Ðz{½u$@G=0?INR&SD>0.5&$>.VWXYZ*�-

ë;BÆJöMÍ3Ðz{.J=±²FG=H$½5@'()*K+,!"ñ&1-2$ô?@INRB<.]^_=OPQBG=&F@=>JVWXYZ*�-?@Mop78PABBz{FG=H

!"#$%&'()*+,-./0,123456789:8;<=>?8@<AB8CDEFGHIJK'KLM,600 µg/100 gNOPQ34RSTQUVWXYZST[7\]^_`aSTQU

!"#$%&'()*+bc278YZMbde,fgh345678i567FjX1khlmno,pqrsQUtuvwxXy8:z8{|A'}8~�8��o8br8�<��&�8�����8�'�'�>8����8c�r8�v2�q�8�oEFGHIJK'KLM,50-340 µg/100 gX34R

���19�����!������X gE¡¢£¤¥R1¦820§FGbc.QnoXYZMH8

�¨290.1 gST¦8©Xª«H8lmno,97.7 g8©sF¬,192.4 gST[/U­/8IJK'

KYZMH8®¯S235 µg/°±[/U5²³S8��°´21SH8noYZMXµ¶·H1°350

gFG5672QU²s1¦8"#$%&'()*+X1°XIJK'KYZMH8¸¹E235 µg/°RX

º»¼Fjb½PQ58¾¿ÀÁÂhIJK'KYZMEº80 µgRbÃ_Q5ÄPrsQUÅ[78ih

IJK'KXÆÇÈSTQlmnoH8¸¹Xº»¼E50 gRXYZb_Q1kbÉÊ.8Ë̼X

300 gXnoHÍXnoSÎk1kb_Q5Ï2U

-Ð/1kh()0ÑNÒÓ672QÔÕT¦Öw×ØÙr8ÚÛ!ÜÝÞb1Qß0àá!26â"#

$%&'ãäbc.Qß0àáâåÜæ��ç#844(3)8p. 967(171)-p. 975(179)82008-

!"#$%&'()*+bc278YZXde,T­¦h2345678èé8�êé8ëé8�ì�é8íé8îïEðñb1[7H10 µgòóT¦R8ôï8tu8A'�'8õ|;<�ö8J÷øù8õ÷õ8ú

û8wx8/.X²8ü¿k8ýþEFGHIJK'KLM,5 µg/100 gFjX34RSTQU

!"#$%&'()*+,-./01234567189:;<=>'K;?@ABCDEFGH.IJK,LM0N;OPQR,STUVWXYZ[I\]^_GH`a^a0N;bcIdebc,fghi;jkh0lm,Ln/op;qrs<=>'KCDt3CDuvIwx_0*+,LM&yzVq

rH<=>'KCDtI{|h}BH~��jGH`e��0��^]��,<=>'KCDtj�B.

*+I0�t;<=>'KCD_Gn/i{|B�p�),BH`a^a0GH��t;<=>'KV��

CDa/.H*+_G��0�t;<=>'K;��CDI{|B��,B]B.^ia�B.`�s0

lm,Ln/I”��as�����V��YHs�,I012^];<=>'K;CDV��,YH

Z[j��_GH”[.����j ¡¢�/.H,i^^£]¤0"#$%&'()*+,¥a0¦§

¨©ª,fg.s�«B�x;<=>'KCDtV¬­a/.HbcI®¯B^ns`

°"#$%&'[<=>'K;±²�),³a/0?\B´µ3¶·;��¸¹

!lm,Ln/0<=>'KCDtj1�µ[a/º»¢�/.sM0¼½;12,¾�/<=>'K¿�1836718VCDa/.HÀÁ0�sÂÃa/CDa/.HÀÁB¯jGM0�p�);ÄZHÅÆB<=>'KCDt;¶·jÇÈ_GH`

!"#$

!%&'()*+,$

!-,$

!*./0$

1234352265789:;5<=5>=5?3@A=5B=5C=5DEF=5GH=&IJK9L5MNOAKPQRSTUVWXWYZ[Z5:;\4000 µg/100 g]5^=\2900 µg/100 g]5<

=\1400 µg/100 g]5>=\1500 µg/100 g]&=9L5MNOAKP_`STUVWaY

1Zb-,cZV5M3d5ef5gh5?ijk35lmAn35opf9L5MNOAKPDcqRSTUVWXWY

1rs5ts5uvs5kw2s5xys\z&{|5EX}&~�5��85XT�&�&��5E9�17-40 µg��S�]L5QRMNOAK�STXWY��)�3�d��&��(9MNOAKL�X

`5�3�s�10 µg/100 g����aY

1��\10 µg/100 g��5��Z��9L16-24 µg/100 gS�])��\5 µg/100 g��]&�

� 9MNOAKL�XWP5¡�L¢£¤MNOAK�_`S�\¥¦5�§5��&¨©~��38-70

µg/100 g]Y

1ª�s\100 g«�¬&MNOAKS­]cZV5®¯ª\210 µg]cX�§ª\120 µg]L¢£¤_

`5°±3lª\42 µg]5H²[ª\36 µg]5³vª\29 µg]L´��5µT�¬ª\11 µg]5¶Tª

c�?·@2¸ª\5 µg]5¹3ºªc»¼½ª\4 µg]5)Zª\¾­]L¿WY

À3Á±AL53-71µg5ÃN3L17-30µgS�YÄ*.&Å5ÆÇÈaª9ÉÊVMNOAKS­PËTaÌÍÎ�¬Y

!ÏÐÑ,$

Ò'(´&MNOAK9ÓWVÔÏÐÑ,�ÕÖ(c-'×&ØÙÚÇ3ÛZWÕÖ(&ÜÇ03\FDE]5ÝÞÂßàeá5âãäå

 æçèéêë'(ìíîïðÂñ�òóôòóõöóö÷øùÑú*ûïòù\üýþ]

1¶ÿE5�W�q5áÏ5F!PW�5"ÓTW�5[#5Uq�q5�$&�5�T§}5�À�L5MNOAKS­P�XW\4 µg/100 g��]Y

1MNOAKL5"#&´��5%9&'("#��a5·@)i*5DEUq+5l@,2±35-.#5

/05¯1\160-640 µg/100 g]9235[#5áÏ)®4&(\160-340 µg/100 g]9_`ST

UVWaY\5/5[#5áÏ5®4&49L5MNOAKPQRSTUVWXWY]

1MNOAKL56�a57È589T�L:å;A<=.�&*.09ÉÊVQR>?ZXWY

1¹@±)Ã<d&AB,9�MNOAKLCD9STUVaP\EUFU5G100 g«�¬MNOAK�

1300c820 µgS�]5HI&ÆÇ­�LJEK`LM9XKXW�NEY